© 2026 Sinochem Nanjing Corporation,
All Right Reserved
People have chased better cancer treatments for a long time. Early chemotherapy pushed limits but damage to healthy cells stayed a major problem. In the 2000s, scientists started noticing how some cancers carry damaged DNA repair genes, like BRCA1 and BRCA2. That’s where the search for a drug like Olaparib began. Researchers at KuDOS Pharmaceuticals built on discoveries around PARP—an enzyme cancer cells with faulty BRCA genes need to fix DNA—and they wondered if blocking PARP could starve tumors while sparing healthy tissue. After plenty of lab work, Olaparib took shape. Clinical trials proved it could shrink tumors in people with gene mutations that left cells powerless against DNA breaks. Approval in Europe and the US soon followed. Decades of struggle against cancer’s tricks went into eight letters: Olaparib.
Olaparib landed on pharmacy shelves as one of the first PARP inhibitors. It treats cancers with specific gene mutations, most notably ovarian and breast cancer with inherited BRCA flaws. The drug comes in tablet and capsule forms, with dosing adjusted for each patient's situation. Its action is targeted, unlike older chemotherapy, which means fewer broad side effects for many patients. Still, careful supervision is a must, because the drug changes how cells manage their DNA breaks, and subtle risks remain. What Olaparib does, though, more than anything, is change the story for people who, not so long ago, faced harsh odds.
As a solid, Olaparib takes the shape of a pale yellow to off-white powder. Its structure is shaped by the fusion of a phthalazinone base and a piperazine ring, giving it the scientific formula C24H23FN4O3. The molecular weight sits at about 434.46 g/mol—substantial for a small molecule drug. It melts above 200°C, showing both stability and chemical strength. Chemists see it as lipophilic, so it dissolves well in organic solvents but barely dissolves in water. This creates challenges for formulation but also means it can cross barriers in the body that keep out many drugs. Its chemical fingerprints include a fluorophenyl moiety and carbonyl groups, which give it both reactivity in synthesis and selectivity when binding to PARP in living cells.
Olaparib comes in tablet or capsule form, usually at strengths of 100 mg or 150 mg for commercial use—the dose a doctor prescribes depends on the type of cancer and the patient’s genetic makeup. Package inserts mandate that users check for enzyme interactions, liver and kidney function, and BRCA gene status before starting treatment. Labeling emphasizes pregnancy risks, since Olaparib can cause harm to the unborn, and flags the need for frequent blood counts and signs of infection during therapy. Pharmacists and nurses handle the drug with gloves, respecting its potential to affect cells in both patients and handlers.
Bringing Olaparib to life demands a series of careful steps that require both skill and attention to detail. Most syntheses start with a phthalazinone scaffold, where chemists introduce various chemical groups through reactions like alkylation and coupling with activated intermediates. Protecting groups shield sensitive spots on the molecule during these steps, and solvents play their part in pulling the right reactions into focus. Multiple purification rounds—using methods such as crystallization or chromatography—clean the product, while analytic tools like NMR and HPLC confirm purity over 99%. Industrial-scale synthesis brings its own hurdles—yield, cost, and environmental waste all shape the batch recipes.
Olaparib’s synthesis leans on a balance of stability and chemical flexibility. Its phthalazinone base can take on a range of modifications: chemists swap out halogen atoms or tweak ring systems to try for better pharmacokinetics, though the main structure stays unchanged in approved drugs. Reaction conditions need to stay slightly acidic to avoid unwanted breakdown. Sometimes, drug developers attach side groups for better blood stability or easier absorption. Researchers have tried both solid phase and solution phase synthesis to streamline production and improve the yield. Post-synthesis modifications might fit the molecule with tracer tags or dye groups for research, making it traceable in cell studies.
The main synonym for Olaparib is AZD2281, its research code during early development at AstraZeneca. Sometimes, it’s described in research as a PARP inhibitor or even by its full chemical name, though that’s a mouthful reserved for the most technical papers. Pharmaceuticals sell Olaparib under the trade name Lynparza, a term recognized worldwide by oncologists and patients navigating genetic testing and targeted therapy.
Hospitals treat Olaparib with respect. Its use matches strict protocols—nurses confirm genetic testing before the pharmacy even releases a dose. People on the medication require regular monitoring for blood cell counts, liver function, and kidney health. Chemo safety cabinets and gloves make up standard procedure for preparation, with leftover drugs managed through hazardous waste channels to protect both staff and the environment. Safety documents alert against handling Olaparib in pregnancy or breastfeeding, and specialized counseling goes to women of childbearing age, as exposure risks could threaten fetal health. Pharmacies keep careful inventory, preventing mistakes in dispensing or exposure.
Olaparib’s legacy grows most in ovarian and breast cancer—types where BRCA mutations cripple DNA repair, letting tumors thrive. It’s also gained ground in prostate and pancreatic cancer with similar genetic backgrounds. Oncologists use Olaparib both as a frontline therapy in newly diagnosed, advanced patients and later on when other tools have lost effect. Clinical trial success means insurance companies in many countries pay for the medication, but gene testing remains a hurdle for some people, especially in lower income areas. Walking alongside other treatments, Olaparib often links with chemo or hormone drugs, giving patients new paths where once only a wall stood.
Back in labs, Olaparib’s story hasn’t plateaued. Scientists dig into how resistant tumors outmaneuver treatment, searching for markers that predict which patients stay responsive longer. Data from years of patient follow-up fuels tweaks in dosing and combination therapy, and genetic analysis seeks hidden patterns in those who relapse. New PARP inhibitors sprout from Olaparib’s blueprint, mixing and matching chemical arms to grapple better with stubborn cancer cell defenses. Researchers also look past cancer, testing PARP inhibitors in conditions like rare blood or neurodegenerative diseases, where DNA repair pathways may matter.
Understanding the downside matters as much as the upside. Researchers learned early that Olaparib can push down blood counts, sometimes dangerously so—anemia, neutropenia, and fatigue appear commonly. Occasional secondary cancers sound alarms, though risk stays smaller than the specter posed by untreated cancer. Animal studies and phased clinical trials tracked heart, liver, and kidney effects, which rarely hit as hard as traditional chemotherapy, yet aren’t zero. Long-term monitoring runs in hospitals and patient advocacy groups, who keep the conversation honest around balancing risks against reward.
Looking down the road, Olaparib will keep changing. Its patent cliff creeps closer, opening generic options and better pricing for struggling health systems. Drug researchers keep tinkering, chasing new cancer types and clever combinations to outwit resistance. Some see opportunity in linking Olaparib with immunotherapy, searching for a one-two punch against cancer’s defenses. Digital health—think wearable devices and AI-driven analysis—may help spot trouble early, improving safety for people on longer courses or when combining therapies. Better gene testing and education could pull more people into the treatment orbit. The story remains unfinished, but Olaparib carved a path where once only rough ground waited, blending the best of careful science with real hope for people in the thick of a tough diagnosis.
Olaparib represents a new chapter for folks fighting some of the most challenging types of cancer, like ovarian and breast cancer linked to BRCA gene mutations. Instead of the old “one size fits all” approach, Olaparib uses what we know about how cancer cells mess up their own DNA. This drug blocks an enzyme called PARP, which these cells rely on to fix their damaged DNA. Without that backup system, those troublesome cells eventually give up and die off.
Talking to friends and families dealing with cancer, I’ve seen what a difference targeted drugs can make. Traditional chemo hits nearly every fast-growing cell in the body, so side effects stack up fast. Olaparib takes aim at the weak spot in tumors with BRCA mutations, hitting hard without turning life wholly upside down. One friend with ovarian cancer spoke about finally feeling good enough to go about her day—or even think about life after cancer. You hear gratitude, but you also hear a kind of relief. It’s not just about survival statistics, but about having energy to laugh with grandkids or plan a trip.
Olaparib earned its stripes in patients with high-grade ovarian cancer that comes back, even after a few rounds of chemo. It’s also making waves in breast cancer, prostate cancer, and pancreatic cancer with BRCA mutations. From what I’ve read and heard at patient support groups, doctors use genetic testing to see who’s likely to beat cancer with this drug. Some insurance plans now cover it because evidence keeps piling up—patients live longer with fewer trips to the hospital.
Even with promising results, not everyone who could benefit gets a prescription. Some people don’t get the right genetic testing, whether it’s because they live in rural areas, face language barriers, or lack solid health coverage. I’ve seen families worry about paying for advanced treatments, or waiting so long for approval they lose precious time. Policy makers and healthcare leaders have work to do. More education for doctors, better funding for rural clinics, and expanded insurance coverage make a real difference.
With drugs like Olaparib, progress feels within reach. The FDA and groups like the American Cancer Society keep a close eye on new treatments, leaning on data from thousands of patients worldwide. In my experience, empowering folks with information and support lifts everybody up—patients feel in control, and families get peace of mind. As research grows, the circle of people whose lives improve keeps getting bigger. That gives me hope, and it pushes the whole community to stay invested in better options for the future.
Taking Olaparib often becomes part of daily life for people with certain cancers, especially ovarian, breast, pancreatic, and prostate cancers. I’ve spoken with oncologists and patients who all describe the process as a rollercoaster—there’s hope from cutting-edge therapy, but also a laundry list of side effects to manage. Doctors prescribe Olaparib mainly as a targeted therapy, using its power to fight cancer cells that have trouble fixing their own DNA. The price is having to deal with how that same effect hits healthy cells, especially the ones that grow or repair quickly.
Fatigue comes up in nearly every conversation, and it’s not the same as missing a few hours of sleep. Patients describe a bone-deep exhaustion that can keep them off their feet, forcing them to rearrange work, chores, and even family time. I’ve watched friends hit by this tiredness, needing to rest after making breakfast or walking the dog.
Nausea and vomiting also hit hard. Studies and patient stories highlight that more than half feel queasy at some point—and it often shows up fast. Eating smaller meals spaced through the day and keeping bland snacks on hand helps a bit. Some also rely on prescribed anti-nausea pills. Even so, some tell me the queasiness lingers in the background, making food less appealing.
An unexpected issue that many mention is loss of appetite. Some people lose interest in their favorite foods, and weight can drop over weeks. This side effect ties into overall weakness and loss of muscle, making recovery tougher. People who stay connected with dietitians often find ways to get needed calories and keep up their strength.
Olaparib affects the bone marrow, causing low counts of red blood cells, white blood cells, and platelets. Fatigue sometimes comes from anemia—low red blood cells. Low white blood cells make it tougher to fight infections. More than one friend told me they felt fine except for a fever, only to find themselves at risk for serious infection. Regular blood tests catch these drops early. Staying away from sick crowds, keeping hands clean, and calling the doctor about fevers can reduce the risks.
Some people have to change up routines because of abdominal pain, diarrhea, or constipation. Doctors may suggest over-the-counter fixes, but these symptoms add another layer of hassle day to day. Mouth ulcers and changes in taste also pop up. Brushing gently, staying hydrated, and using mouth rinses make a difference for some.
Muscle and joint aches are common, too. These aches can keep folks from joining in on family walks or other activities they used to enjoy. Warm compresses, rest, and gentle stretching have helped some patients manage these aches.
Cancer always brings uncertainty, and new therapies hold so much promise. Olaparib doesn’t just affect cancer cells. Knowing what kind of side effects might surface really matters. I’ve heard over and over that people feel more confident tackling problems when they track symptoms and talk openly with doctors or nurses. Adjusting doses, changing medicines, or connecting with counselors and specialists often keeps side effects from taking over daily life. Sharing real experiences with friends, care teams, and support groups provides comfort and practical advice that can’t be found in pamphlets.
Olaparib shows up as a bright spot for many folks fighting certain cancers, especially ovarian, breast, and prostate cancer linked with BRCA gene mutations. This medication works by targeting cancer cells more specifically, often giving people another shot even after other treatments start failing. Taking this drug the right way actually makes a difference—missing doses or swallowing it the wrong way can take away some of the edge it offers.
Tablets or capsules usually come in distinct strengths. Doctors tend to prescribe it as two separate doses each day, about twelve hours apart. Skipping pills or bunching doses together brings trouble. Blood levels swing too high or too low. In my own experience supporting a close family member on Olaparib, consistent timing helped keep side effects measured and improved recovery days.
Some people have trouble swallowing pills, especially if they’re not feeling strong. Olaparib tablets aren’t meant to be chewed or opened—each pill comes with a special coating for a reason. Crushing or cutting up the tablets destroys this layer, changes how the medicine works, and could even irritate the mouth or throat. A glass of water helps send it down smoothly.
Healthcare professionals flag this up front. Anyone struggling to swallow tablets should tell their cancer care team before making moves to chop up pills. Facilities might offer solutions—not every treatment fits every patient’s needs.
Olaparib doesn’t mind food. Some pills react differently depending on what’s in the stomach. In this case, researchers actually checked the effects both ways. Patients can eat before or after the dose. In practical terms, that helps when side effects like nausea hit hard. Eating a light snack might give some comfort if pills start to churn the stomach.
Some doctors advise taking Olaparib in the middle of a meal routine—not because food changes absorption, but because daily habits make it easier to remember. Tying a life-saving drug to a cup of morning tea or evening supper turns it into less of a chore. People need routines, especially during treatment.
For many people, chemotherapy, radiation, and every other appointment quickly fill up the calendar. Tossing another drug into the mix brings stress. Setting alarms on the phone or filling a weekly pillbox prevented mistakes in my house. At the pharmacy, double-checking the packaging also helped—Olaparib tablets and capsules come in different dosages, and swallowing the wrong strength by accident can have real consequences.
Cancer care teams usually offer support for these logistics. Pharmacists, nurses, and caregivers all bring their own experience to the table. Sometimes the solution comes from talking openly in the waiting room or support group. Nobody should feel embarrassed to ask about pill swallowing techniques or tricks for remembering if it’s time for the next dose.
Fatigue, nausea, and low blood counts tend to show up for people using Olaparib. Any new symptom deserves a mention at the next check-in. Sometimes a dose adjustment brings relief, or another medication steps in to tackle nausea or pain. Speed matters—waiting too long to flag a side effect can let things spiral.
If someone forgets a dose, doctors usually recommend skipping the missed pill and picking up again at the next regular time. Doubling up isn’t safe. The best advice often comes from people who’ve walked this path or worked closely with families navigating these new routines.
Olaparib grabbed headlines for giving hope to people with certain cancers, especially ovarian, breast, pancreatic, and prostate cancers linked to BRCA gene mutations. This drug belongs to a class called PARP inhibitors, which basically disrupt cancer cells’ ability to repair themselves. Oncologists use this targeted approach to try to stall cancer growth. Olaparib isn’t a blanket solution for everyone, though. Some people face more risks than benefits.
Anyone living with serious kidney or liver trouble should steer clear of Olaparib unless a specialist insists the benefits outweigh the risks. The body filters and breaks down this drug through these organs. If they’re working poorly, Olaparib builds up and toxicity becomes much more likely. For folks in this category, blood and urine tests can show just how badly these organs are struggling. I’ve seen patients in the clinic who assumed a pill would be easy on the body, but their lab results told another story—any stress on an already overworked system caused complications. Doctors often seek other options for them.
Healthy bone marrow keeps red cells, white cells, and platelets at the right level. Trouble starts when cancer therapies—including Olaparib—mess with this factory. If you’re already facing low blood counts from another reason, especially conditions like myelodysplastic syndromes or acute myeloid leukemia (AML), Olaparib can tip the scale further in the wrong direction. Studies from the FDA and real-world experience both confirm a key fact: this medication sometimes causes severe anemia, infections, and even life-threatening bleeding in the wrong group.
Doctors usually avoid prescribing Olaparib to pregnant or nursing mothers. Animal studies have shown birth defects and risk to babies. It made sense to me every time I saw an oncologist ask women of childbearing age for a pregnancy test before starting this medication. If there’s a chance of pregnancy, the answer is a firm no. Chemotherapy already comes with risks to fertility, but Olaparib introduces new dangers to fetal development that can’t be ignored.
Drug allergies stick with you. If you’ve had hives, trouble breathing, or swelling after taking Olaparib or other PARP inhibitors before, it’s not worth gambling again. I’ve seen allergic reactions transform a manageable situation into a medical emergency within minutes. It’s not a common issue, but this red flag can’t be brushed aside.
Drug interactions seem dry on paper but wreak havoc in real life. Certain antifungals, antibiotics, anti-seizure medicines, and even grapefruit juice mess with Olaparib’s breakdown in the body. This can push side effects into dangerous territory or knock effectiveness off balance. Oncologists spend a lot of time drilling into each patient’s medicine list—no detail is too small. If you forget to mention prescriptions, over-the-counter pills, or herbal supplements, things can snowball quickly.
Trust between patient and cancer team matters most. Honest talk about medical history, current conditions, and everything you’re taking builds a safety net. Bloodwork and organ checks before and during treatment help spot trouble early. Everyone deserves information for making good decisions, so clear questions and answers must be the norm.
Most people walking into a big-city hospital know cancer makes doctors pull out all the stops. You see teams marching down hallways, charts in hand, huddling over scans, and debating drug combos that did not exist ten years ago. It’s rarely about picking just one pill and calling it a day. Olaparib, originally rolled out for certain ovarian and breast cancers tied to BRCA mutations, shows up in more of these hallway debates lately.
Having spent time supporting friends going through chemotherapy, I have seen how Olaparib gets talked about alongside different treatments. There’s a reason: it targets cancer cells' DNA repair mechanisms, a different angle from the one hit by chemo or immunotherapy. The FDA agreed after clinical trials proved Olaparib allowed some people to go longer without their cancer returning, especially when paired with older chemo drugs or after new ones finished their punch.
Patients bring different bodies, genes, and histories. No single approach covers every scenario. Chemotherapy has long battered cancer cells, but sneaky ones crawl away, learn how to duck attacks, and grow back. By weaving Olaparib in with a platinum-based chemotherapy or even some of the newer immunotherapies, doctors can often land a second or third blow at just the right time.
Randomized studies show that in certain advanced breast and ovarian cancers, pairing Olaparib with existing treatments buys valuable time — slowing progression and, in some cases, helping people feel stronger for longer. Some patients stay out of the infusion chair for more weeks or months. I remember one family friend lighting up over a much-postponed birthday trip she got to enjoy because her maintenance routine now included a dose of Olaparib.
Pairing drugs doesn’t always mean more hope. Every extra pill carries side effects — fatigue, nausea, low blood counts take their toll on daily routines. Some people land in the hospital because those risks stack up quickly. My neighbor once had to pause chemo because, combined with Olaparib, it meant more days spent managing fevers than tackling groceries or chores. The danger of overloading the body needs thoughtful attention from the medical team.
Cancer doctors keep testing dozens of drug combinations, logging patient reactions, and learning from trial data, not guesswork. Hospitals with strong communications between oncologists, pharmacists, and specialists catch side effects early and tweak plans as they go. Patients getting these combos want honest heads-up conversations — no one likes surprises about intense side effects or sudden changes. Trusted doctors, along with updated guidelines from cancer societies, help families weigh the risks and benefits.
Insurance issues lurk in the background, sometimes blocking access to the latest combinations, even if doctors agree they’re worth the shot. Advocacy from patient groups and clear evidence from clinical trials help push treatments into everyday reality, not just research journals. Looking forward, more research will open up new pairings and safer checkpoints, so patients can face tough treatments with more confidence.
| Names | |
| Preferred IUPAC name | N-[(4-[(3-[(4-cyclopropylcarbonylpiperazin-1-yl)carbonyl]-4-fluorophenyl)methyl]phthalazin-1-yl)carbamoyl]acetamide |
| Other names |
AZD-2281 KU-0059436 Lynparza |
| Pronunciation | /oʊˈlæp.ə.rɪb/ |
| Identifiers | |
| CAS Number | 763113-22-0 |
| Beilstein Reference | 2909729 |
| ChEBI | CHEBI:88289 |
| ChEMBL | CHEMBL2067377 |
| ChemSpider | 21534641 |
| DrugBank | DB09074 |
| ECHA InfoCard | ECHA InfoCard: 100000193334 |
| EC Number | 2.5.1.59 |
| Gmelin Reference | 1267004 |
| KEGG | D08144 |
| MeSH | D000077224 |
| PubChem CID | 23725625 |
| RTECS number | KVQ6Z0V3XE |
| UNII | Q8N5N7D72M |
| CompTox Dashboard (EPA) | DTXSID4087702 |
| Properties | |
| Chemical formula | C24H23FN4O3 |
| Molar mass | 434.458 g/mol |
| Appearance | White to off-white powder |
| Odor | Odorless |
| Density | 1.4 g/cm3 |
| Solubility in water | Slightly soluble |
| log P | 2.26 |
| Vapor pressure | 2.92E-21 mmHg |
| Acidity (pKa) | 13.80 |
| Basicity (pKb) | 12.29 |
| Magnetic susceptibility (χ) | -42.1·10^-6 cm³/mol |
| Refractive index (nD) | 1.576 |
| Dipole moment | 4.13 D |
| Thermochemistry | |
| Std molar entropy (S⦵298) | 373.6 J·mol⁻¹·K⁻¹ |
| Std enthalpy of combustion (ΔcH⦵298) | -10584.6 kJ/mol |
| Pharmacology | |
| ATC code | L01XX46 |
| Hazards | |
| Main hazards | May cause cancer; may damage fertility or the unborn child; causes serious eye irritation; may cause drowsiness or dizziness. |
| GHS labelling | GHS07, GHS08 |
| Pictograms | Harmful, Prescription only, Use in pregnancy contraindicated |
| Signal word | Warning |
| Hazard statements | H361d: Suspected of damaging the unborn child. |
| Precautionary statements | Keep out of reach of children. If medical advice is needed, have product container or label at hand. |
| Flash point | > 260°C |
| Lethal dose or concentration | LD50 (rat, oral): > 2000 mg/kg |
| LD50 (median dose) | LD50 (median dose) of Olaparib: >2000 mg/kg (rat, oral) |
| NIOSH | NOS45000 |
| PEL (Permissible) | 0.001 mg/m³ |
| REL (Recommended) | 300 mg twice daily |
| IDLH (Immediate danger) | IDLH not established |
| Related compounds | |
| Related compounds |
Nicotinamide Rucaparib Veliparib Niraparib Talazoparib |
